Lipoprotein(a) and ischemic heart disease--a causal association? A review.

[1]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[2]  Børge G Nordestgaard,et al.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.

[3]  Florian Kronenberg,et al.  Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: A systematic in-depth review , 2009, Experimental Gerontology.

[4]  Benjamin J. Wright,et al.  Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease , 2009, Nature Genetics.

[5]  B. Nordestgaard,et al.  Pentanucleotide repeat polymorphism, lipoprotein(a) levels, and risk of ischemic heart disease. , 2008, The Journal of clinical endocrinology and metabolism.

[6]  Mark J Graham,et al.  Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice , 2008, Circulation.

[7]  Mary J. Malloy,et al.  Analysis of 17,576 Potentially Functional SNPs in Three Case–Control Studies of Myocardial Infarction , 2008, PloS one.

[8]  P. Ridker,et al.  Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. , 2008, Journal of the American College of Cardiology.

[9]  A. Scanu,et al.  Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. , 2008, The American journal of cardiology.

[10]  B. Nordestgaard,et al.  Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study , 2008 .

[11]  Thomas Lumley,et al.  Association of Gene Variants With Incident Myocardial Infarction in the Cardiovascular Health Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[12]  E. Topol,et al.  A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[13]  F. Kronenberg,et al.  Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[14]  A. Valerio,et al.  Different apoprotein(a) isoform proportions in serum and carotid plaque. , 2007, Atherosclerosis.

[15]  F. Kronenberg,et al.  In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. , 2007, Kidney international.

[16]  J. Cole,et al.  Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. , 2007, Clinical chemistry.

[17]  P. Ridker,et al.  Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. , 2006, JAMA.

[18]  F. Kronenberg,et al.  Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. , 2006, Journal of the American College of Cardiology.

[19]  P. Fratino,et al.  Lipoprotein(a), apolipoprotein(a) polymorphism and coronary atherosclerosis severity in type 2 diabetic patients. , 2006, International journal of cardiology.

[20]  L. Smeeth,et al.  Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. , 2006, American journal of epidemiology.

[21]  S. Greenland,et al.  Causation and causal inference in epidemiology. , 2005, American journal of public health.

[22]  M. Koschinsky,et al.  An Apolipoprotein(a) Peptide Delays Chylomicron Remnant Clearance and Increases Plasma Remnant Lipoproteins and Atherosclerosis In Vivo , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[23]  E. Brilakis,et al.  Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. , 2005, The New England journal of medicine.

[24]  N. Powe,et al.  High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[25]  F. Kronenberg.  Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease , 2004, Expert review of cardiovascular therapy.

[26]  P. Ridker,et al.  Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study. , 2004, Clinical chemistry.

[27]  Arjun Deb,et al.  Lipoprotein(a): New insights into mechanisms of atherogenesis and thrombosis , 2004, Clinical cardiology.

[28]  M. Boffa,et al.  Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. , 2004, Clinical biochemistry.

[29]  S. Ebrahim,et al.  Mendelian randomization: prospects, potentials, and limitations. , 2004, International journal of epidemiology.

[30]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[31]  G. Utermann,et al.  The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration , 1992, Human Genetics.

[32]  E. Boerwinkle,et al.  Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups , 1991, Human Genetics.

[33]  G. Getz,et al.  Lysine-Phosphatidylcholine Adducts in Kringle V Impart Unique Immunological and Potential Pro-inflammatory Properties to Human Apolipoprotein(a)* , 2003, Journal of Biological Chemistry.

[34]  A. Ariyo,et al.  Lp(a) lipoprotein, vascular disease, and mortality in the elderly. , 2003, The New England journal of medicine.

[35]  M. Koschinsky,et al.  Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. , 2003, Clinical chemistry.

[36]  M. Koschinsky,et al.  Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside , 2003, Current opinion in lipidology.

[37]  Ling Liu,et al.  Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. , 2003, Clinical chemistry.

[38]  L. M. Srivastava,et al.  Analysis of the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease. , 2003, Atherosclerosis.

[39]  R. Hui,et al.  Pentanucleotide TTTTA Repeat Polymorphism of Apolipoprotein(a) Gene and Plasma Lipoprotein(a) Are Associated With Ischemic and Hemorrhagic Stroke in Chinese: A Multicenter Case-Control Study in China , 2003, Stroke.

[40]  C. Hengstenberg,et al.  Association of Polymorphisms of the Apolipoprotein(a) Gene With Lipoprotein(a) Levels and Myocardial Infarction , 2003, Circulation.

[41]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[42]  Huijun Sun,et al.  Lipoprotein(a) Enhances Advanced Atherosclerosis and Vascular Calcification in WHHL Transgenic Rabbits Expressing Human Apolipoprotein(a)* , 2002, Journal of Biological Chemistry.

[43]  K. Aihara,et al.  Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. , 2002, Clinical chemistry.

[44]  M. Navab,et al.  Oxidized lipids as mediators of coronary heart disease , 2002, Current opinion in lipidology.

[45]  A. Capurso,et al.  APO(a) variants and lipoprotein(a) in men with or without myocardial infarction. , 2002, Experimental and molecular pathology.

[46]  A. Evans,et al.  Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. , 2002, Atherosclerosis.

[47]  O. Klezovitch,et al.  Stimulation of Interleukin-8 Production in Human THP-1 Macrophages by Apolipoprotein(a) , 2001, The Journal of Biological Chemistry.

[48]  R. Simari,et al.  Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. , 2001, Blood.

[49]  David Clayton,et al.  Epidemiological methods for studying genes and environmental factors in complex diseases , 2001, The Lancet.

[50]  A. Sharrett,et al.  Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Circulation.

[51]  A. von Eckardstein,et al.  Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. , 2001, Journal of the American College of Cardiology.

[52]  Huijun Sun,et al.  Transgenic Rabbits Expressing Human Apolipoprotein(a) Develop More Extensive Atherosclerotic Lesions in Response to a Cholesterol-Rich Diet , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[53]  M. Myerson,et al.  High Levels of Lp(a) With a Small Apo(a) Isoform Are Associated With Coronary Artery Disease in African American and White Men , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[54]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[55]  E. Vittinghoff,et al.  Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. , 2000, JAMA.

[56]  O. Røsby,et al.  LPA gene: interaction between the apolipoprotein(a) size (‘kringle IV’ repeat) polymorphism and a pentanucleotide repeat polymorphism influences Lp(a) lipoprotein level , 2000, Journal of internal medicine.

[57]  F. Laporte,et al.  Contribution of apolipoprotein(a) size, pentanucleotide TTTTA repeat and C/T(+93) polymorphisms of the apo(a) gene to regulation of lipoprotein(a) plasma levels in a population of young European Caucasians. , 1999, Atherosclerosis.

[58]  F. Kronenberg,et al.  Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. , 1999, Circulation.

[59]  D. Arveiler,et al.  Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study. , 1999, Atherosclerosis.

[60]  F. Kronenberg,et al.  The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. , 1999, Journal of the American Society of Nephrology : JASN.

[61]  P. Fratino,et al.  Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. , 1999, Journal of the American College of Cardiology.

[62]  M. Koschinsky,et al.  Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  J. Haddow,et al.  Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. , 1998, Clinical chemistry.

[64]  N. Rifai,et al.  International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators. , 1998, Clinical chemistry.

[65]  B. Nordestgaard,et al.  Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[66]  G. Dagenais,et al.  Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. , 1998, Journal of the American College of Cardiology.

[67]  G. Utermann,et al.  The number of kringle IV repeats 3-10 is invariable in the human apo(a) gene. , 1998, Gene.

[68]  G. Utermann,et al.  Significant impact of the +93 C/T polymorphism in the apolipoprotein(a) gene on Lp(a) concentrations in Africans but not in Caucasians: confounding effect of linkage disequilibrium. , 1998, Human molecular genetics.

[69]  F. Kronenberg,et al.  Concentrations of the atherogenic Lp(a) are elevated in FH. , 1998, European journal of human genetics : EJHG.

[70]  P. Harpel,et al.  Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. , 1997, Circulation.

[71]  M. Koschinsky,et al.  Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. , 1997, Circulation.

[72]  F. Kronenberg,et al.  Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. , 1997, Journal of lipid research.

[73]  M. Schroll,et al.  Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. , 1997, Atherosclerosis.

[74]  B. Nordestgaard,et al.  In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[75]  S. Fortmann,et al.  A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[76]  G. Utermann,et al.  The Number of Identical Kringle IV Repeats in Apolipoprotein(a) Affects Its Processing and Secretion by HepG2 Cells* , 1996, The Journal of Biological Chemistry.

[77]  F. Kronenberg,et al.  Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[78]  B. Nordestgaard,et al.  Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta. , 1996, The Journal of clinical investigation.

[79]  T. Arinami,et al.  Apolipoprotein(a) size and pentanucleotide repeat polymorphisms are associated with the degree of atherosclerosis in coronary heart disease , 1996 .

[80]  F. Kronenberg,et al.  Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[81]  B. Nordestgaard,et al.  Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. , 1996, Circulation research.

[82]  E. Janus,et al.  Frequency Distributions of Apolipoprotein(a) Kringle IV Repeat Alleles and Their Effects on Lipoprotein(a) Levels in Caucasian, Asian, and African Populations: The Distribution of Null Alleles Is Non-Random , 1996, European journal of human genetics : EJHG.

[83]  B. G. Brown,et al.  Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). , 1995, JAMA.

[84]  B. Nordestgaard,et al.  Transfer of lipoprotein(a) and LDL into aortic intima in normal and in cholesterol-fed rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[85]  F. Acquati,et al.  Ten allelic apolipoprotein[a] 5' flanking fragments exhibit comparable promoter activities in HepG2 cells. , 1995, Journal of lipid research.

[86]  F. Kronenberg,et al.  A pentanucleotide repeat polymorphism in the 5' control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. , 1995, The Journal of clinical investigation.

[87]  D. Rader,et al.  The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. , 1995, The Journal of clinical investigation.

[88]  B. Furie,et al.  Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis , 1995, Nature Medicine.

[89]  M. Koschinsky,et al.  Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). , 1995, Clinical chemistry.

[90]  R. Lawn,et al.  Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice , 1994, Nature.

[91]  D. Rader,et al.  Quantitation of Plasma Apolipoproteins in the Primary and Secondary Prevention of Coronary Artery Disease , 1994, Annals of Internal Medicine.

[92]  J. Salonen,et al.  Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. , 1994, Atherosclerosis.

[93]  P. Ridker,et al.  A prospective study of lipoprotein(a) and the risk of myocardial infarction. , 1993, JAMA.

[94]  H. Hobbs,et al.  Molecular definition of the extreme size polymorphism in apolipoprotein(a). , 1993, Human molecular genetics.

[95]  P. Weissberg,et al.  Proliferation of human smooth muscle cells promoted by lipoprotein(a). , 1993, Science.

[96]  P. Wilson,et al.  Effects of Age, Sex, and Menopausal Status on Plasma Lipoprotein(a) Levels The Framingham Offspring Study , 1993, Circulation.

[97]  Y. Friedlander,et al.  Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the Jerusalem population. , 1993, Atherosclerosis.

[98]  R. Hammer,et al.  Atherogenesis in transgenic mice expressing human apolipoprotein(a) , 1992, Nature.

[99]  E. Boerwinkle,et al.  Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[100]  E. Boerwinkle,et al.  Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. , 1992, The Journal of clinical investigation.

[101]  A. Scanu,et al.  Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. , 1992, The Journal of biological chemistry.

[102]  K. Hajjar,et al.  Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. , 1991, The Journal of biological chemistry.

[103]  E. Boerwinkle,et al.  Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. , 1990, The New England journal of medicine.

[104]  J. Loscalzo,et al.  Lipoprotein(a), fibrin binding, and plasminogen activation. , 1990, Arteriosclerosis.

[105]  A. Hamsten,et al.  Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid , 1989, Journal of internal medicine.

[106]  M. Dietel,et al.  Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. , 1989, Arteriosclerosis.

[107]  J. Breslow,et al.  Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis , 1989, Nature.

[108]  A. Scanu,et al.  A potential basis for the thrombotic risks associated with lipoprotein(a) , 1989, Nature.

[109]  E. Chen,et al.  cDNA sequence of human apolipoprotein(a) is homologous to plasminogen , 1987, Nature.

[110]  M. Katan.  APOUPOPROTEIN E ISOFORMS, SERUM CHOLESTEROL, AND CANCER , 1986, The Lancet.

[111]  Tm Brouwers,et al.  VIRUS-INFECTION OF URINARY-TRACT , 1974 .

[112]  K. Berg.  A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM. , 2009, Acta pathologica et microbiologica Scandinavica.